Gyre Therapeutics, Inc.
GYRE
$8.61
-$0.20-2.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -99.00K | 1.12M | 3.53M | 7.53M | -101.01M |
| Total Depreciation and Amortization | 471.00K | 454.00K | 238.00K | 425.00K | 308.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 685.00K | 1.85M | 1.04M | 1.97M | 93.33M |
| Change in Net Operating Assets | -3.82M | -1.70M | -10.30M | -7.05M | 10.73M |
| Cash from Operations | -2.76M | 1.73M | -5.49M | 2.88M | 3.36M |
| Capital Expenditure | 65.00K | -693.00K | -1.46M | -231.00K | -2.32M |
| Sale of Property, Plant, and Equipment | 138.00K | -5.00K | 218.00K | 50.00K | 167.00K |
| Cash Acquisitions | -- | -- | -- | -- | 5.46M |
| Divestitures | -- | -- | -- | -- | -566.00K |
| Other Investing Activities | -2.21M | -1.69M | -7.04M | -7.04M | -1.40M |
| Cash from Investing | -2.00M | -2.39M | -8.27M | -7.22M | 1.34M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.33M | 374.00K | 275.00K | 658.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 2.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -367.00K | -50.00K | -119.00K | -- | -- |
| Cash from Financing | 964.00K | 324.00K | 156.00K | 658.00K | 2.50M |
| Foreign Exchange rate Adjustments | -255.00K | 106.00K | -78.00K | -46.00K | 231.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.05M | -231.00K | -13.69M | -3.72M | 7.43M |